Skip to main content
SpringerLink
Log in

Immunohistochemical determination of her2 expression in breast cancer from core biopsy specimens: a reliable predictor of her2 status of the whole tumor

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

HER2 overexpression in breast cancer is associated with a poor prognosis, resistance to endocrine therapy and chemosensitivity to anthracyclines and paclitaxel. Moreover, trastuzumab (HerceptinR) shows therapeutic benefit in patients with HER2 overexpressing tumors. Therefore, knowledge of the pretherapeutical HER2 status allows an optimal selection of patients for treatment. In addition to a definitive histological diagnosis, core biopsies of tumors offer the opportunity to evaluate the HER2 status preoperatively. In 64 patients with invasive breast cancer, sections of core biopsies and of the subsequently removed whole tumor were investigated immuno-histochemically with the DAKO HercepTestTM. Fifteen tumors (23%) revealed HER2 overexpression, and 44 tumors (69%) were negative in both, the core biopsy and the whole tumor sections. Two core biopsies were negative whereas the corresponding final specimen was 2+ positive. In 3 cases weak overexpression was observed in the core biopsy, but the whole tumor was negative. The overall concordance of the results achieved at core biopsy and whole tumor sections was 92% κ=0.8). A negative HER2 result on core biopsy was never associated with a score 3+ tumor specimen nor was there a case of negative whole tumor specimen with a preceding 3+ score in the biopsy. If one demands the highest degree of overexpression (3+), 100% of our study patients would have been selected correctly using the results on core biopsy alone. We thus conclude, that the immunohistochemical investigation of core biopsies offers the opportunity for a valid preoperative estimation of HER2 overexpression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Roh H, Pippin J, Drebin JA: Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu. Cancer Res 60: 560-565, 2000

    Google Scholar 

  2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987

    Google Scholar 

  3. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SA, Killander D, MyGuire WL: HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50: 4332-4337, 1990

    Google Scholar 

  4. Lovekin C, Ellis IO, Locker A, Robertson JF, Bell J, Nicholson R, Gullick WJ, Elston CW, Blamey RW: C-erb B2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63: 439-443, 1991

    Google Scholar 

  5. Ross JS, Fletcher JA: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 79: 27-33, 1998

    Google Scholar 

  6. Dowsett M, Cooke T, Ellis I, Gullick WJ, Gusterson B, Mallon E, Walker R: Assessment of HER2 status in breast cancer: why, when and how? Eur J Cancer 36: 170-176, 2000

    Google Scholar 

  7. Quenel N, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM: The prognostic value of cerbB2 in primary breast carcinomas: A study of 942 cases. Breast Cancer Res Treat 35: 283-291, 1995

    Google Scholar 

  8. Wright C, Nicholson S, Angus B, Sainsbury JR, Farndon J, Cairns J, Harris AL, Horne CH: Relationship between CerbB-2 prote in product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65: 118-121, 1992

    Google Scholar 

  9. Berns EM, Foekens JA, van Staveren IL, van Putten WL, de Koning HY, Portengen H, Klijn JG: Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 159: 11-18, 1995

    Google Scholar 

  10. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco AR, De Placiod S: C-erbB2 overexpression decreases the benefit of adjuvant Tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14: 2702-2708, 1996

    Google Scholar 

  11. Newby JC, Johnston SRD, Smith IE, Dowsett M: Expression of epidermal growth factor receptor and C-erb B2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 3: 1643-1651, 1997

    Google Scholar 

  12. Yamauchi H, O'Neill A, Gelman R, Carney W, Tenney DY, Hosch S, Hayes DF: Prediction of response to antoestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extraxcellular domain of the HER-2/c-neu protein. J Clin Oncol 15: 2518-2525, 1997

    Google Scholar 

  13. Menard S, Tagliabue E, Campiglio M, Pupa SM: Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 182: 150-162, 2000

    Google Scholar 

  14. Stal O, Sullivan S, Wingren S, Skoog L, Rutquist LE, Carstensen JM, Nordenskjold B: C-erbB2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 31: 2185-2190, 1995

    Google Scholar 

  15. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M: C-erb-B2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330: 1260-1266, 1994

    Google Scholar 

  16. Baselga J, Seidman AD, Rosen PP, Norton L: HER-2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology 11: 43-48, 1997

    Google Scholar 

  17. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285-4289, 1992

    Google Scholar 

  18. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklar in NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twadell T, Henderson IC, Norton L: Phase II study of weekly intravenous recombinant humanized antip185HER2 monoclonal antibody in patients with HER-2/neu overexpressing metastatic breast cancer. J Clin Oncol 14: 737-744, 1996

    Google Scholar 

  19. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twadell T, Glaspy JA, Slamon DJ: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16: 2659-2671, 1998

    Google Scholar 

  20. Shak S: Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin multinational investigator study group. Semin Oncol 26: 71-77, 1999

    Google Scholar 

  21. Cobleigh MA, Cogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficiacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has origressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648, 1999

    Google Scholar 

  22. Goldenberg MM: Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for treatment of metastatic breast cancer. Clin-Ther 21: 309-318, 1999

    Google Scholar 

  23. Parker SH, Burbank F, Jackman RJ, Aucreman CJ, Cardenosa G, Cink TM, Coscia JL Jr., Eklund GW, Evans WP, Garver PR: Percutaneous large-core breast biopsy: a multi-institutional study. Radiology 193: 359-364, 1994

    Google Scholar 

  24. Agresti A.: Categorial Data Analysis. Wiley, New York, 1990, p. 365

    Google Scholar 

  25. King TA, Cederbom GJ, Champaign JL, Smetherman DH, Bolton JS, Farr GH, McKinnon WM, Kuske RR, Fuhrman GM: A core biopsy diagnosis of invasive carcinoma allows for definitive surgical treatment planning. Am J Surg 176: 497-501, 1998

    Google Scholar 

  26. Gotzinger P, Gebhard B, Gnant M, Rudas M, Reiner A, Jakesz R: Value of punch biopsy in diagnosis of palpable breast tumors. A prospective study of 150 patients. Chirurg 69: 1068-1071, 1998

    Google Scholar 

  27. Puglisi F, Scalone S, Bazzocchi M, Fabris C, Cacitti V, Beltrami CA, Di Loreto C: Image-guided core breast biopsy: a suitable method for preoperative biological characterization of small (pT1) breast carcinomas. Cancer Lett 133: 223-229, 1998

    Google Scholar 

  28. Winstanley J, Cooke T, Murray GD, Holt S, Croton R, Griffiths K, Nicholson R: The long term significance of C-erb B2 in primary breast cancer. Br J Cancer 63: 447-450, 1991

    Google Scholar 

  29. Seshadri R, Firgaira FA, Horsefall DJ: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 11: 1936-1942, 1993

    Google Scholar 

  30. Press MJ, Bernste in L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15: 2894-2904, 1997

    Google Scholar 

  31. Pegram MD, Pauletti G, Slamon DJ: HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 52: 65-77, 1998

    Google Scholar 

  32. Johnson RC, Ricci A Jr, Cartun RW, Ackroyd R, Tsongalis GJ: p185HER2 overexpression in human breast cancer using molecular and immunohistochemical methods. Cancer Invest 18: 336-342, 2000

    Google Scholar 

  33. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ: Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 17: 1974-1982, 1999

    Google Scholar 

  34. Hoang MP, Sahin AA, Ordonez NG, Sneige N: HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast cancer. Am J Clin Pathol 113: 852-859, 2000

    Google Scholar 

  35. Klijanienko J, Couturier J, Galut M, El Naggar AK, Maciorowski Z, Padoy E, Mosseri V, Vielh P: Detection and quantitation by fluorscence in-situ hybridization (FISH) and image analysis of HER-2/neu gene amplification in breast cancer fine-needle samples. Cancer 87: 312-318, 1999

    Google Scholar 

  36. Wu JT, Zhang P, Bentz JS: Quantification of HER2 oncoprotein in fine-needle aspirates of the breast. Ann Clin Lab Sci 30: 49-56, 2000

    Google Scholar 

  37. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR: Pathologic findings from the national surgical adjuvant breast and bowel project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8: 103-112, 1990

    Google Scholar 

  38. Parkes HC, Lillycrop K, Howell A, Craig RK: C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DANN amplification and correlation with prognosis. Br J Cancer 61: 39-45, 1990

    Google Scholar 

  39. Howell A, Harland RN, Barnes DM, Hayward E, Redford J, Swindell R, Sellwood RA: Endocrine therapy for advanced carcinoma of the breast: effect of tumor heterogeneity and site of biopsy on the predictive value of progesterone receptor estimations. Cancer Res 47: 296-299, 1987

    Google Scholar 

  40. Marth C, Fuith LC, Bock G, Daxenbichler G, Dapunt O: Modulation of ovarian carcinoma tumor marker CA-125 by gamma-interferon. Cancer Res 49: 6538-6542, 1989

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Innsbruck University Hospital, Austria

    Elisabeth Mueller-Holzner, Vroni Fink & Christian Marth

  2. Department of Radiology II, Innsbruck University Hospital, Austria

    Thomas Frede

Authors
  1. Elisabeth Mueller-Holzner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vroni Fink
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas Frede
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christian Marth
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mueller-Holzner, E., Fink, V., Frede, T. et al. Immunohistochemical determination of her2 expression in breast cancer from core biopsy specimens: a reliable predictor of her2 status of the whole tumor. Breast Cancer Res Treat 69, 13–19 (2001). https://doi.org/10.1023/A:1012281221647

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1012281221647

Search

Navigation